Acrivon Therapeutics Showcases AP3 Platform at Leading Conferences
Acrivon Therapeutics, Inc. is set to demonstrate its innovative AP3 platform at two prominent scientific conferences within the upcoming days. This promising platform plays a pivotal role in the streamlined drug discovery and clinical advancement, particularly for its leading candidates, ACR-368 and ACR-2316.
Understanding the AP3 Platform
The Acrivon Predictive Precision Proteomics (AP3) platform represents a sophisticated approach in precision medicine aimed at identifying clinical biomarkers. This capability has been crucial for ACR-368, which is entering a Phase 2b study. The OncoSignature assay developed through AP3 has shown statistically significant results in validating patient responses. ACR-2316, also enabled by the AP3 compilation, demonstrates remarkable potential as a WEE1/PKMYT1 inhibitor with superior activity observed in initial studies.
Importance of Upcoming Presentations
At the Human Proteome Organization (HUPO) World Congress and the EORTC-NCI-AACR Symposium, Acrivon scientists will share their findings, highlighting how AP3 empowers clinical development. According to Kristina Masson, Ph.D., Acrivon’s dedication to harnessing cutting-edge technology has led to compelling discoveries that aid in overcoming challenges in biomarker discovery and tumor treatment resistance.
Details of Presentations
The following details outline the upcoming presentations at the HUPO 2024 World Congress:
- Title: Acrivon Predictive Precision Proteomics (AP3)-guided development and prospective clinical registrational-intent Phase 2 validation of the response-predictive OncoSignature test for ACR-368
- Session: Clinical Proteomics I
- Session Date and Time: Presentation scheduled for October 21, from 1:15 p.m. – 3:15 p.m. CEST
- Poster ID Number: P-I-0346
- Abstract Number: 525
Additionally, the ACR-2316 presentation is scheduled as follows:
- Title: ACR-2316: a potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
- Session: Clinical Proteomics II
- Session Date and Time: October 22, from 1:00 p.m. – 3:00 p.m. CEST
- Poster ID Number: P-II-0624
- Abstract Number: 513
ENA 2024 Symposium Presentation Features
At the ENA 2024 Symposium, Acrivon will also present details about ACR-2316:
- Title: Rational design of ACR-2316, a novel, potent WEE1/PKMYT1 inhibitor with superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
- Session Title: DNA Repair Modulation
- Session Date and Time: October 25, from 9:00 a.m. – 3:00 p.m. CEST
- Poster Board Number: PB318
Acrivon’s Commitment to Innovation
Acrivon Therapeutics is focused on developing precision oncology treatments tailored to individual patient profiles. Their proprietary platform, AP3, enables the measurement of compound-specific actions on tumor signaling and resistance mechanisms. This technology not only optimizes drug development but also assists in identifying patients best suited for these therapies.
Currently, Acrivon is advancing ACR-368, a selective small molecule inhibitor aimed at CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various tumors. The company has gained Fast Track designation from the FDA, which marks a significant milestone in its ongoing clinical journey. Results from recent studies highlight a confirmed overall response rate and compelling data on patient selection based on the OncoSignature test.
Looking Ahead
As Acrivon continues navigating the complexities of drug development, the outcomes and insights gleaned from its advanced presentations are expected to be instrumental in fostering innovation within the biopharmaceutical industry. The unique applications of the AP3 platform signal exciting possibilities not only for Acrivon’s therapies but also for the future of personalized medicine.
Frequently Asked Questions
What is the AP3 platform used for?
The AP3 platform is used for drug discovery and clinical development, helping identify biomarkers and optimize treatment designs.
When will the presentations take place?
The presentations will occur on October 21 and 22, 2024, at the HUPO World Congress and on October 25, 2024, at the ENA 2024 Symposium.
What are the key candidates being discussed?
The candidates discussed include ACR-368 and ACR-2316, two innovative treatments in cancer therapy.
What achievements has Acrivon made with ACR-368?
Acrivon has gained Fast Track designation from the FDA and has reported positive clinical data in its trials for ovarian and endometrial cancer.
How does Acrivon help tailor treatments for patients?
Acrivon utilizes its proprietary AP3 platform to match patients to treatments based on predicted sensitivity, enhancing personalized medicine approaches.
